Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Mar 31, 2025
Revenue declined in the current quarter compared with the prior quarter. The result also fell relative to the same quarter one year earlier.
Key takeaway
Quarter ended Mar 31, 2025 · FY2025 Q1
Revenue declined in the current quarter compared with the prior quarter. The result also fell relative to the same quarter one year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3B
Revenue reported for this quarter.
Quarter-over-quarter
-20.1%
Change from the immediately preceding quarter.
Year-over-year
-3.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$14.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2024 | $3.5B | +12.3% |
| Sep 30, 2024 | $3.7B | +10.6% |
| Dec 31, 2024 | $3.8B | +10.3% |
| Mar 31, 2025 | $3B | -3.7% |
Revenue performance
The reported revenue decreased from the immediately preceding quarter, continuing a reversal from the growth trend seen in earlier quarters of the fiscal year.
Quarterly comparison
Compared with the same quarter one year ago, revenue was lower. The sequential decline from the prior quarter was steeper than the year-over-year decline.
What to watch
The filing context does not provide specific causes for the revenue change; monitor future filings for any operational or market developments.